For discussion: do you prescribe/allow vaginal estrogens in patients receiving adjuvant endocrine therapy with aromatase inhibitors? In this Danish observational study, there was not an increased risk of recurrence or mortality with vaginal or systemic hormone therapy, but in a subset of patients using AIs in the adjuvant setting, an increased...

Conclusion: The administration of CURC following ABE may be a therapeutic agent in preventing liver damage.

Conclusion/Relevance: The kinetics signal of Pertuzumab in combination with Trastuzumab binding to HER2 was detected in real time. Experimental results demonstrated that both Trastuzumab and Pertuzumab can be captured by HER2, but the former was significantly superior to the latter in terms of the target number. Additionally, the binding speed...

Clinical Relevance: Sarcopenia and obesity seem to predict negative outcomes in many oncologic entities. Their prevalence and impact in current breast cancer care are promising but still controversial.

Conclusion: SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR /HER2– advanced breast cancer and limited treatment options.